Health ❯ Healthcare ❯ Pharmaceuticals ❯ Drug Development

Immunotherapy

MoonLake Investors Get Deadline Reminder as Securities Suits Mount Over Sonelokimab Trial

The suits contend MoonLake overstated sonelokimab’s Nanobody advantages over BIMZELX after trial data coincided with a near-90% one-day share drop.

FDA Approves Libtayo as First Immunotherapy for Adjuvant Treatment of High‑Risk CSCC